Prostacyclin biosynthesis in essential hypertension before and during treatment

Journal of Human Hypertension

Volumn 10, Issue 1, 1996, Pages 37-42

  Ritter, J M ^a,b   Brett, S E ^a   Woods, J D ^a   Benjamin, N ^a   Stratton, P D ^a   Barrow, S E ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Amlodipine; Bendrofluazide; Essential hypertension; Metoprolol; Prostacyclin; Quinapril; Terazosin

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 6 OXOPROSTAGLANDIN F1 ALPHA; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; METOPROLOL FUMARATE; PROSTACYCLIN; QUINAPRIL; TERAZOSIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENDROFLUMETHIAZIDE; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION; ISOQUINOLINES; MALE; METOPROLOL; MIDDLE AGED; TETRAHYDROISOQUINOLINES; THROMBOXANE A2; THROMBOXANE B2;

EID: 0030040568     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979; 300: 1142-1147.
2. McGiff JC, Vane JR. Prostaglandins and the regulation of blood pressure. Kidney Int 1975; 8: S262-S270.
3. Dunn MJ, Gröne HJT. The relevance of prostaglandins in human hypertension. In: Neri Serneri GG, McGiff JC, Paoletti R, Born GVR (eds). Advances in Prostaglandin, Thromboxane and Leukotriene Research. Raven Press: New York, 1985, vol 13, pp 455-460.
4. Nasjletti A, Baer PG. Prostanoids in experimental and clinical hypertension. In: Haluschka PV, Mais DE (eds). Eicosanoids in the Cardiovascular and Renal Systems. MTP Press: Lancaster, 1988, pp 159-175.
5. 2 by intact and homogenized aortae from the developing spontaneously hypertensive rat. Biochim Biophys Acta 1979; 574: 177-181.
6. Uehara Y, Ishii M, Ishimitsu T, Sugimoto T. Enhanced phospholipase C activity in the vascular wall of spontaneously hypertensive rats. Hypertension 1988; 11: 28-33.
7. Tobian L, Uehara Y, Iwai J. Prostaglandin alterations in barely hypertensive Dahl S rats. Trans Assoc Am Physicians 1985; 98: 378-383.
8. 2 in Dahl salt-sensitive and salt-resistant rats. Hypertension 1983; 5: 537-544.
9. Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil. N Engl J Med 1989; 320: 1037-1043.
10. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension 1990; 15: 469-474.
11. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Int Med 1993; 153: 477-484.
12. Oates JA. Antagonism of antihypertensive drug therapy by non-steroidal anti-inflammatory drugs. Hypertension 1988, 11(Suppl II): II4-II6.
13. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharm 1990; 30: 519-526.
14. 2-like activity from the rat aorta: effect of captopril, furosemide and sodium. Prostaglandins 1981; 22: 575-585.
15. Ciabattoni G, Pugliesi F, Cinotti GA. Characterization of furosemide-induced activation of the renal prostaglandin system. Eur J Pharmacol 1979; 60: 181-187.
16. 2 by the aorta of spontaneously hypertensive rats. J Pharmacol Exp Ther 1990; 235: 207-213.
17. Jackson EK, Campbell WB. A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins. Hypertension 1981; 3: 23-33.
18. White WB, Lund-Johanson P, McCabe EJ, Omvik P. Clinical evaluation of the Accutracker II ambulatory blood pressure monitor: assessment of performance in two countries and comparison with sphygmomanometry and intra-arterial blood pressure at rest and during exercise. J Hypertens 1989; 7: 967-975.
19. 2 production in healthy subjects. Thromb Res 1980; 17: 317-327.
20. ABPI Data Sheet Compendium, Datapharm Publications Limited, 12 Whitehall, London, UK.
21. Barrow SE et al. Cigarette smoking: profiles of thromboxane and prostacyclin derived products in human urine. Biochim Biophys Acta 1989; 993: 121-127.
22. 2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018.
23. Patrono C et al. Evidence for the direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 1982; 69: 231-239.
24. Uehara Y et al. Possible role of prostacyclin synthase in altered prostacyclin generation in DOCA-salt hypertensive rats. Am J Hypertens 1991; 4: 667-673.
25. FitzGerald GA, Smith B, Pederson AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068.
26. 2 in normotensive and hypertensive subjects on varying sodium intakes. Hypertension 1982; 4: 735-742.
27. 1α in man. J Biol Chem 1980; 255: 10194-10198.
28. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272-1276.
29. Fischer S, Bernutz C, Meier H, Weber PC. Formation of prostacyclin and thromboxane in man as measured by the main urinary metabolites. Biochim Biophys Acta 1986; 876: 194-199.
30. 2 and prostacyclin, in randomly sampled males, with special reference to the influence of inheritance and environmental factors. Clin Sci 1990; 79: 639-645.
31. 2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 1993; 22: 197-203.
32. Kramer HJ, Düsing R, Stinnesbeck B. Interaction of conventional and antikaliuretic diuretics with the renal prostaglandin system. Clin Sci 1980; 59: 67-70.
33. Beckmann ML et al. Propranolol increases prostacyclin synthesis in patients with essential hypertension. Hypertension 1988; 12: 582-588.
34. Moore TJ et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981; 3: 168-173.
35. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kailikrein-kinin system. J Hypertens 1987; 5: 121-128.
36. 2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients. Prostaglandins Leukotrienes Med 1983; 11: 143-150.
37. Barrow SE et al. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmac 1986; 87: 243-247.
38. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991; 18: 558-563.
39. Metha JL. Influence of calcium channel blockers on platelet function and arachidonic acid metabolism. Am J Cardiol 1985; 55: 158B-164B.
40. Salveti A et al. Nifedipine interactions in hypertensive patients. Cardiovasc Drugs Ther 1990; 4(Suppl 5) 963-968.
41. Minuz P et al. Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition. Br J Clin Pharm 1995; 39: 45-50.